Your session is about to expire
← Back to Search
Procedure
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution for Keratoconus
Phase 1 & 2
Waitlist Available
Led By S. Lance Forstot, M.D.
Research Sponsored by Colorado Eye Consultants/Cornea Consultants of Colorado
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Summary
This trial will test a new machine that uses a different method to do cross-linking, to see if it is effective and safe.
Eligible Conditions
- Pellucid Marginal Corneal Degeneration
- Keratoconus
- Corneal Ectasia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Corrected distance visual acuity
Secondary outcome measures
Keratometry
Uncorrected visual acuity
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Pulsed, AcceleratedExperimental Treatment1 Intervention
5 mW, 10 sec on, 10 sec off, 24 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Group II: ConventionalActive Control1 Intervention
4 mW, 10 sec on, 10 sec off, 30 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
2020
Completed Phase 1
~200
Find a Location
Who is running the clinical trial?
Colorado Eye Consultants/Cornea Consultants of ColoradoLead Sponsor
S. Lance Forstot, M.D.Principal InvestigatorColorado Eye Consultants/Corneal Consultants of Colorado
Share this study with friends
Copy Link
Messenger